Clinical trial
Combination Chemotherapy and Rituximab in Treating Patients With Chronic…
NCT00309881 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00309881 |
|---|---|
| Title | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) |
| Official title | CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate |
| Enrollment | 75 |
| Start date | Apr 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2011 |
| First posted | Apr 3, 2006 |
| Last update posted | Oct 3, 2016 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: